Truist Reduces Price Target for PROCEPT BioRobotics Corporation (PRCT) to $50 from $64, Maintains Buy Rating
Price Target Adjustment: Truist has reduced the price target for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) from $64 to $50 while maintaining a Buy rating, anticipating healthy Q3 earnings but also potential stock volatility.
Company Overview: PROCEPT BioRobotics is a surgical robotics company focused on urology, known for its AquaBeam Robotic System, which is used in minimally invasive surgeries. Despite its potential, some analysts suggest that certain AI stocks may offer better investment opportunities.
Trade with 70% Backtested Accuracy
Analyst Views on PRCT
About PRCT
About the author
Chicago Capital Reduces Stake in PROCEPT BioRobotics
- Stake Reduction Details: Chicago Capital disclosed a reduction of 377,850 shares in PROCEPT BioRobotics during Q4, translating to an estimated $12.53 million trade, indicating a potential loss of confidence as the remaining stake is valued at $37.47 million.
- Ownership Percentage Shift: Following the sale, Chicago Capital's stake in PROCEPT decreased from 1.38% to 0.93%, reflecting a diminished focus on the company within its portfolio, which may impact market sentiment towards the stock.
- Company Financial Performance: Despite PROCEPT achieving a 43% revenue increase in Q3 to $83.3 million, its stock has plummeted over 60% in the past year, raising concerns about its ability to achieve sustainable profitability amidst ongoing operating losses.
- Future Outlook: Management has projected revenue for 2026 to be between $410 million and $430 million, implying up to 32% growth from 2025 levels, yet high operational losses and spending remain critical concerns for investors.
Chicago Capital Reduces PRCT Stake
- Share Reduction Details: Chicago Capital sold 377,850 shares of PRCT in Q4, with an estimated transaction value of $12.53 million, indicating a decrease in confidence towards the stock.
- Position Value Decline: As of December 31, the value of Chicago Capital's PRCT holdings was $37.47 million, down $18.52 million from the previous quarter, reflecting the dual impact of trading activities and stock price movements.
- Market Performance Comparison: PRCT's stock price has plummeted 60.4% over the past year, significantly underperforming the S&P 500's approximately 14% gain, highlighting market concerns regarding its future profitability.
- Growth Potential vs. Risks: Despite a 43% year-over-year revenue increase to $83.3 million in Q3 and management's revenue guidance of $410 million to $430 million for 2026, ongoing operating losses and high expenditures raise doubts about sustainable profitability, affecting investor sentiment.
PRCT Options Analysis: Put Contract Offers 4.4% YieldBoost Potential
- Put Contract Yield: The $25.00 put contract for PRCT has a current bid of $1.10, and if an investor sells to open this contract, they commit to buying shares at $25.00, resulting in a cost basis of $23.90, which represents a 17% discount compared to the current price of $30.29, making it attractive for potential buyers.
- Expiration Risk Analysis: Current data suggests a 79% chance that the put contract will expire worthless, which would yield a 4.40% return on the cash commitment, or an annualized yield of 27.71%, referred to as YieldBoost, highlighting the contract's appeal.
- Call Contract Returns: The $32.50 call contract for PRCT has a current bid of $2.00, and if an investor buys shares at $30.29 and sells this contract, they could achieve a total return of 13.90% if the stock is called away at expiration, showcasing the potential profitability of this strategy.
- Volatility Comparison: The implied volatility for the put contract is 74%, while for the call contract it is 81%, compared to an actual trailing twelve-month volatility of 54%, indicating a high market expectation for future price fluctuations in PRCT stock, necessitating careful risk assessment by investors.
ETFs on the Move This Monday: REMX, IHI
ETF Performance: The iShares U.S. Medical Devices ETF is underperforming, down approximately 1.7% in Monday afternoon trading.
Weakest Components: Notable declines among ETF components include Axogen, which fell by about 4.9%, and Procept Biorobotics, down by about 4.2%.
Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
PROCEPT BioRobotics to Highlight Aquablation Expansion at Upcoming Piper Sandler Event
Company Presentation: PROCEPT BioRobotics Corp. will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, focusing on its Aquablation therapy and HYDROS Robotic System.
Financial Performance: For Q3 2025, PROCEPT reported a net loss of $21.4 million, despite a 43% increase in revenue to $83.3 million, driven by strong demand for its products.
Revenue Growth: U.S. revenue rose to $73.9 million, a 42% increase from the previous year, while international revenue grew by 53% to $9.4 million, indicating strong market adoption.
Future Outlook: The company anticipates full-year revenue of approximately $325.5 million for fiscal 2025, up from $224.5 million in 2024, supported by a solid cash position of $297.3 million.
TD Cowen Keeps Buy Rating on PROCEPT BioRobotics, Reduces Price Target to $50
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
Chicago Capital Reduces Stake in PROCEPT BioRobotics
- Stake Reduction Details: Chicago Capital disclosed a reduction of 377,850 shares in PROCEPT BioRobotics during Q4, translating to an estimated $12.53 million trade, indicating a potential loss of confidence as the remaining stake is valued at $37.47 million.
- Ownership Percentage Shift: Following the sale, Chicago Capital's stake in PROCEPT decreased from 1.38% to 0.93%, reflecting a diminished focus on the company within its portfolio, which may impact market sentiment towards the stock.
- Company Financial Performance: Despite PROCEPT achieving a 43% revenue increase in Q3 to $83.3 million, its stock has plummeted over 60% in the past year, raising concerns about its ability to achieve sustainable profitability amidst ongoing operating losses.
- Future Outlook: Management has projected revenue for 2026 to be between $410 million and $430 million, implying up to 32% growth from 2025 levels, yet high operational losses and spending remain critical concerns for investors.
Chicago Capital Reduces PRCT Stake
- Share Reduction Details: Chicago Capital sold 377,850 shares of PRCT in Q4, with an estimated transaction value of $12.53 million, indicating a decrease in confidence towards the stock.
- Position Value Decline: As of December 31, the value of Chicago Capital's PRCT holdings was $37.47 million, down $18.52 million from the previous quarter, reflecting the dual impact of trading activities and stock price movements.
- Market Performance Comparison: PRCT's stock price has plummeted 60.4% over the past year, significantly underperforming the S&P 500's approximately 14% gain, highlighting market concerns regarding its future profitability.
- Growth Potential vs. Risks: Despite a 43% year-over-year revenue increase to $83.3 million in Q3 and management's revenue guidance of $410 million to $430 million for 2026, ongoing operating losses and high expenditures raise doubts about sustainable profitability, affecting investor sentiment.
PRCT Options Analysis: Put Contract Offers 4.4% YieldBoost Potential
- Put Contract Yield: The $25.00 put contract for PRCT has a current bid of $1.10, and if an investor sells to open this contract, they commit to buying shares at $25.00, resulting in a cost basis of $23.90, which represents a 17% discount compared to the current price of $30.29, making it attractive for potential buyers.
- Expiration Risk Analysis: Current data suggests a 79% chance that the put contract will expire worthless, which would yield a 4.40% return on the cash commitment, or an annualized yield of 27.71%, referred to as YieldBoost, highlighting the contract's appeal.
- Call Contract Returns: The $32.50 call contract for PRCT has a current bid of $2.00, and if an investor buys shares at $30.29 and sells this contract, they could achieve a total return of 13.90% if the stock is called away at expiration, showcasing the potential profitability of this strategy.
- Volatility Comparison: The implied volatility for the put contract is 74%, while for the call contract it is 81%, compared to an actual trailing twelve-month volatility of 54%, indicating a high market expectation for future price fluctuations in PRCT stock, necessitating careful risk assessment by investors.
ETFs on the Move This Monday: REMX, IHI
ETF Performance: The iShares U.S. Medical Devices ETF is underperforming, down approximately 1.7% in Monday afternoon trading.
Weakest Components: Notable declines among ETF components include Axogen, which fell by about 4.9%, and Procept Biorobotics, down by about 4.2%.
Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
PROCEPT BioRobotics to Highlight Aquablation Expansion at Upcoming Piper Sandler Event
Company Presentation: PROCEPT BioRobotics Corp. will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, focusing on its Aquablation therapy and HYDROS Robotic System.
Financial Performance: For Q3 2025, PROCEPT reported a net loss of $21.4 million, despite a 43% increase in revenue to $83.3 million, driven by strong demand for its products.
Revenue Growth: U.S. revenue rose to $73.9 million, a 42% increase from the previous year, while international revenue grew by 53% to $9.4 million, indicating strong market adoption.
Future Outlook: The company anticipates full-year revenue of approximately $325.5 million for fiscal 2025, up from $224.5 million in 2024, supported by a solid cash position of $297.3 million.
TD Cowen Keeps Buy Rating on PROCEPT BioRobotics, Reduces Price Target to $50
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
